Human melanoma cells express functional receptors for thyroid-stimulating hormone

Endocrine-Related Cancer

Volumn 13, Issue 4, 2006, Pages 1269-1277

  Ellerhorst, Julie A ^a   Sendi Naderi, Aresu ^b   Johnson, Marilyn K ^a   Cooke, Carolyn P ^a   Dang, Shyam M ^a   Diwan, A Hafeez ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; MITOGEN ACTIVATED PROTEIN KINASE; THYROTROPIN RECEPTOR;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CIRCULATION; CONTROLLED STUDY; DYSPLASTIC NEVUS; HUMAN; HUMAN CELL; HYPOTHYROIDISM; IMMUNOFLUORESCENCE; MELANOCYTE; MELANOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC AMP; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOTHYROIDISM; IMMUNOENZYME TECHNIQUES; MELANOCYTES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; NEVUS, PIGMENTED; POLYMERASE CHAIN REACTION; RECEPTORS, THYROTROPIN; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; THYROTROPIN;

EID: 33846827368     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01239     Document Type: Article

References (20)

1. Brokken LJS, Bakker O, Wiersinga WM & Prummel MF 2005 Functional thyrotropin receptor expression in the pituitary folliculo-stellate cell line TtT/GF. Experimental and Clinical Endocrinology & Diabetes 113 13-20.
2. Chazenbalk GD, Kakinuma A, Jaume JC, McLachlan SM & Rapoport B 1996 Evidence for negative cooperativity among human thyrotropin receptors overexpressed in mammalian cells. Endocrinology 137 4586-4591.
3. De Vita G, Berlingieri MT, Visconti R, Castellone MD, Viglietto G, Baldassarre G, Zannini M, Bellacosa A, Tsichlis PN, Fusco A et al. 2000 Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. Cancer Research 60 3916-3920.
4. Dremier S, Coulonval K, Perpete S, Vandeput F, Fortemaison N, Van Keymeulen A, Deleu S, Ledent C, Clement S, Schurmans S et al. 2002 The role of cyclic AMP and its effect on protein kinase A in the mitogenic action of thyrotropin on the thyroid cell. Annals of the New York Academy of Sciences 968 106-121.
5. Ellerhorst JA, Cooksley CD & Grimm EA 2001 Autoimmunity and hypothyroidism in patients with uveal melanoma. Melanoma Research 11 633-637.
6. Ellerhorst JA, Cooksley CD, Broemeling L, Johnson MM & Grimm EA 2003 High prevalence of hypothyroidism among patients with cutaneous melanoma. Oncology Reports 10 1317-1320.
7. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J & Tallini G 2003 Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology 21 3226-3235.
8. Georgopoulos NA, Sykiotis GP, Sgourou A, Papachatzopoulou A, Markou KB, Kyriazopoulou V, Papavassiliou AG & Vagenakis AG 2003 Autonomously functioning thyroid nodules in a former iodine-deficient area commonly harbor gain-of-function mutations in the thyrotropin signaling pathway. European Journal of Endocrinology 149 287-292.
9. Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ, Shih W & Gorski DH 2005 Detection of B-RAF and N-RAS mutations in human melanoma. Journal of the American College of Surgery 200 362-370.
10. Icovelli L, Capobianco L, Salvatore L, Sallese M & D'Ancona GM 2001 Thyrotropin activates mitogen-activated protein kinase pathway in FRTL-5 by a cAMP-dependent protein kinase A-independent mechanism. Molecular Pharmacology 60 924-933.
11. Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, Rosenberg SA & Schwartzentruber DJ 1995 Thyroid dysfunction in 281 patients with metastatic melanoma or renal cancer treated with interleukin-2 alone. Journal of Immunotherapy with Emphasis on Tumor Immunology 4 272-278.
12. Martin A, Huber GK & Davies TF 1990 Induction of human thyroid cell ICAM-1(CD54) antigen expression and ICAM-1mediated lymphocyte binding. Endocrinology 127 51-657.
13. Misrahi M, Ghinea N, Sar S, Saunier B, Jolivet A, Loosfelt H, Cerutti M, Devauchelle G & Milgrom E 1994 Processing of the precursors of the human thyroid-stimulating hormone receptor in various eukaryotic cells (human thyrocytes, transfected L cells and baculovirus-infected insect cells). European Journal of Biochemistry 222 711-719.
14. Porcellini A, Fenzi G & Avvedimento EV 1997 Mutations of the thyrotropin receptor gene. Journal of Molecular Medicine 75 567-575.
15. Poser I & Bosserhoff AK 2004 Transcription factors involved in development and progression of malignant melanoma. Histology and Histopathology 19 173-188.
16. Robertson GP 2005 Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Reviews 24 273-285.
17. Slominski A, Wortsman J, Kohn L, Ain KB, Venkataraman GM, Pisarchik A, Chung JH, Giuliani C, Thornton M, Slugocki G et al. 2002 Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. Journal of Investigative Dermatology 119 1449-1455.
18. Smalley KSM 2003 A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? International Journal of Cancer 104 527-532.
19. Suh JM, Song JH, Kim DW, Kim H, Chung HK, Hwang JH, Kim JM, Hwang ES, Chung J, Han JH et al. 2003 Regulation of the phosphatidylinositol 3-kinase. Akt/-protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland. Journal of Biological Chemistry 24 21960-21971.
20. Xing M 2005 BRAF mutation in thyroid cancer. Endocrine-Related Cancer 12 245-262.